Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE versus KENALOG 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE versus KENALOG 40.
Betamethasone vs KENALOG-40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression, resulting in anti-inflammatory and immunosuppressive effects. It also suppresses the hypothalamic-pituitary-adrenal axis.
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; suppresses cytokine production, inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and stabilizes lysosomal membranes.
0.6 to 9 mg/day orally in divided doses; intramuscularly, 0.5 to 9 mg/day; intravenously, up to 12 mg/day; topical (as valerate or dipropionate) applied thinly to affected area once to twice daily.
Intra-articular injection: 10-40 mg for large joints, 5-15 mg for medium joints, 2.5-5 mg for small joints. Intralesional injection: 2.5-5 mg per lesion. Intramuscular injection: 40-80 mg once monthly. Not for IV or subcutaneous use.
None Documented
None Documented
Clinical Note
moderateBetamethasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin."
Clinical Note
moderateBetamethasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin."
Clinical Note
moderateBetamethasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 6.4 hours (range 4.3-9.4 hours). Clinically, adrenal suppression lasts 2.7-3.5 days after single dose.
Terminal elimination half-life is approximately 2 to 3 hours after IV administration, but due to the triamcinolone acetonide suspension formulation, the effective half-life following intramuscular or intra-articular administration is prolonged to 2-3 weeks due to slow dissolution from the injection site.
Primarily renal: ~60% as metabolites, <5% unchanged. Biliary/fecal: ~15-20%.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites. Less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for approximately 15-20% of total clearance.
Category A/B
Category C
Corticosteroid
Corticosteroid
Betamethasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin."